🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525256-29-00
Authorised Phase I

Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

2026-525256-29-00 · tracked via the Priya Life Science EU tracker
Sponsor
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
04/03/2026
Enrollment target
36
Sites
Czechia

Condition studied

Comparative bioavailability study under fasting conditions

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525256-29-00 on CTIS ↗ ← All trials in the EU